Industry News
In brief: Uscom, Antisense, Gropep, Bresagen
Sydney's Uscom (ASX:UCM) has responded to ASX's 'please explain' as to why its shares dropped from $1.40 on 10 May to a low of $1.00 on 17 May. [ + ]
Epitan and pSivida complete sustained-release study
A proof of concept study by Melbourne's Epitan (ASX:EPT) and nanotechnology company pSivida (ASX:PSD) has found that pSivida's BioSilicon technology can be used in a liquid-based sustained-release formulation of Epitan's tanning drug Melanotan. [ + ]
CSL opens new $33 million influenza vaccine centre
A new $33 million influenza vaccine centre has officially been opened at CSL premises in Parkville. [ + ]
NHMRC to establish national clinical trials register
The National Health and Medical Research Council (NHMRC) is to spend AUD$1.5 million to establish a national clinical trials register. [ + ]
Marine invader under monitoring
Scientists have developed a genetic tool to help environmental authorities monitor the spread and impact of Australia's most invasive marine species, the New Zealand screwshell.
[ + ]Progen encouraged by pilot trial results
A Phase IIa pilot trial of its promising PI-88 angiogenesis inhibitor in patients with advanced melanoma has convinced Brisbane cancer-drug developer Progen Industries (ASX: PGL, NASDAQ: PGLAF) to move its lead compound into a Phase IIb trial. [ + ]
New $1.1m cancer unit opens at the Garvan
The prime minister has officially opened the Australian Cancer Research Foundation (ACRF) Unit for Molecular Genetics of Cancer at Garvan Institute of Medical Research in Sydney. [ + ]
Chief scientist quits
Chief scientist, Dr Robin Batterham, has accepted a full time position with Rio Tinto and will not seek reappointment as Australia's senior science advisor for a third term. [ + ]
Eiffel looking to cut costs
Drug re-engineering company Eiffel (ASX:EIF) has issued shares worth a total of $70,000 as part of the cancellation of an employee contract, and is looking to cut costs. [ + ]
Avastra trial delayed
The clinical trial being run by Sydney biomaterials company Avastra (ASX:AVS) for its BioWeld device has been delayed by six months due to severe post-operative complications experienced by the first patient. [ + ]
Florey director reflects on a revolution in neuroscience
Eminent Melbourne neuroscientist Prof Fred Meldelsohn, director of Melbourne's Howard Florey Institute, is the Bethlehem Griffiths Research Foundation medallist for 2005. [ + ]
ARRM opts for voluntary receivership
Sources close to Adelaide-based Advanced Rapid Robotic Manufacturing have revealed that the company has gone into voluntary receivership. [ + ]
Non-viral vectors deliver genes
A gene therapy method that doesn't rely on potentially toxic viruses as vectors may be growing closer as the result of in vitro research results reported by University at Buffalo scientists in the current online issue of the Proceedings of the National Academy of Sciences.
[ + ]Select Vaccines licenses hepatitis E antibodies
Melbourne's Select Vaccines (ASX:SLT) announced today it has licensed serologicals company Upstate USA to market and distribute Select's five proprietary monoclonal antibodies to hepatitis E virus for research purposes. [ + ]
